Your browser doesn't support javascript.
loading
Developmental toxicity of lersivirine in rabbits when administered throughout organogenesis and when limited to sensitive windows of axial skeletal development.
Campion, Sarah N; Bowman, Christopher J; Cappon, Gregg D; Harrison, Anthony; Finch, Gregory L; Hurtt, Mark E.
Afiliación
  • Campion SN; Drug Safety Research and Development, Pfizer Worldwide Research & Development, Groton, CT 06340, USA. sarah.campion@pfizer.com
Birth Defects Res B Dev Reprod Toxicol ; 95(3): 250-61, 2012 Jun.
Article en En | MEDLINE | ID: mdl-22495820
ABSTRACT

BACKGROUND:

Lersivirine is a second-generation nonnucleoside reverse transcriptase inhibitor undergoing clinical development for the treatment of human immunodeficiency virus-1. An embryo-fetal development study was performed to evaluate the potential for maternal and developmental toxicity of lersivirine.

METHODS:

Pregnant New Zealand White rabbits were administered 0, 100, 250, and 500 mg/kg lersivirine by oral gavage once daily on gestation days (GDs) 7 to 19, followed by cesarean section on GD 29 and fetal evaluation.

RESULTS:

Maternal toxicity was noted at all dose levels (decreased food consumption and body weight gain), with fetal toxicity at 500 mg/kg (decreased fetal weights, increased postimplantation loss). Equivocal findings for axial skeletal malformations were observed in three fetuses at 500 mg/kg. To better understand if these malformations were related to treatment with lersivirine, a follow-up rabbit embryo-fetal development study was performed with 1000 mg/kg/day lersivirine (500 mg/kg BID, 12-hr interdose interval) for two different 3-day windows, GDs 8 to 10 or GDs 11 to 13, which represent the sensitive windows of axial skeletal development in rabbits. Control rabbits were administered vehicle following the same dosing regimen from GDs 8 to 13. Cesarean sections were performed on GD 29, and fetal skeletons were examined for the potential of lersivirine to cause skeletal malformations in rabbits. At maternal exposure levels higher than the initial study, lersivirine did not induce fetal skeletal malformations when administered in the sensitive windows of axial skeletal development.

CONCLUSION:

The results of these studies indicate that lersivirine did not exhibit any evidence of teratogenicity in rabbits.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Desarrollo Óseo / Pruebas de Toxicidad / Organogénesis / Desarrollo Embrionario / Nitrilos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Female / Humans / Pregnancy Idioma: En Revista: Birth Defects Res B Dev Reprod Toxicol Asunto de la revista: TERATOLOGIA / TOXICOLOGIA Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Desarrollo Óseo / Pruebas de Toxicidad / Organogénesis / Desarrollo Embrionario / Nitrilos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Female / Humans / Pregnancy Idioma: En Revista: Birth Defects Res B Dev Reprod Toxicol Asunto de la revista: TERATOLOGIA / TOXICOLOGIA Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos
...